Bristol Myers Squibb (CELG-RI) Notes Payables (2009 - 2016)
Bristol Myers Squibb (CELG-RI) posted quarterly Notes Payables of $155.0 million for Q2 2016, down 79.47% year-over-year from $755.0 million in Q3 2015, and up 46.23% quarter-over-quarter from $106.0 million in Q1 2016.
Bristol Myers Squibb (CELG-RI) Notes Payables (2009 - 2016) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Notes Payables for 8 consecutive years, with $155.0 million the latest figure, recorded in Q2 2016.
- In Q2 2016, Notes Payables fell 79.47% year-over-year to $155.0 million; the TTM figure through Jun 2016 stood at $155.0 million (down 79.47% YoY), while the FY2015 annual figure was $139.0 million, down 76.44% from the prior year.
- Notes Payables grew to $155.0 million in Q2 2016 per CELG-RI's latest filing, from $106.0 million in the prior quarter.
- Across five years, Notes Payables topped out at $1.4 billion in Q1 2013 and bottomed at $106.0 million in Q1 2016.
- Historically, Notes Payables has averaged $494.3 million across 5 years, with a median of $383.0 million in 2014.
- Annual changes were most pronounced in 2013 — Notes Payables surged 846.21% — and 2014, when it tumbled 79.52%.
- Bristol Myers Squibb's Notes Payables stood at $826.0 million in 2012, then slumped by 56.54% to $359.0 million in 2013, then soared by 64.35% to $590.0 million in 2014, then tumbled by 76.44% to $139.0 million in 2015, then grew by 11.51% to $155.0 million in 2016.
- Business Quant data shows CELG-RI's Notes Payables at $155.0 million in Q2 2016, $106.0 million in Q1 2016, and $139.0 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 155.00 Mn |
| Mar 31, 2016 | 106.00 Mn |
| Dec 31, 2015 | 139.00 Mn |
| Sep 30, 2015 | 642.00 Mn |
| Jun 30, 2015 | 755.00 Mn |
| Mar 31, 2015 | 330.00 Mn |
| Dec 31, 2014 | 590.00 Mn |
| Sep 30, 2014 | 401.00 Mn |
| Jun 30, 2014 | 365.00 Mn |
| Mar 31, 2014 | 281.00 Mn |
| Dec 31, 2013 | 359.00 Mn |
| Sep 30, 2013 | 680.00 Mn |
| Jun 30, 2013 | 764.00 Mn |
| Mar 31, 2013 | 1.37 Bn |
| Dec 31, 2012 | 826.00 Mn |
| Sep 30, 2012 | 751.00 Mn |
| Jun 30, 2012 | 236.00 Mn |
| Mar 31, 2012 | 145.00 Mn |
| Dec 31, 2011 | 2.00 Mn |
| Sep 30, 2011 | 182.00 Mn |